Patents Examined by Nick Zou
  • Patent number: 9994859
    Abstract: The present invention relates to a method of producing HPV pseudovirions in plant cells, the plant produced pseudovirions per se, a neutralization assay using the plant produced pseudovirions and pharmaceutical compositions comprising the plant produced pseudovirions.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: June 12, 2018
    Assignee: University of Cape Town
    Inventors: Edward P Rybicki, Inga Isabel Hitzeroth
  • Patent number: 9868762
    Abstract: The invention relates to a method for purifying compositions containing virus-like particles (VLP), wherein a VLP-containing composition is filtered through a filter medium, in particular through a membrane, having a molecular weight cut off (MWCO) of more than 30 kDa, and the cell culture supernatant of VLP-expressing cells is used as a VLP-containing composition. The invention further relates to a VLP-containing composition which can be produced by this method.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: January 16, 2018
    Assignee: LIFE SCIENCE INKUBATOR BETRIEBS GMBH & CO. KG
    Inventors: Victoria Demina, Heiko Manninga
  • Patent number: 9822162
    Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: November 21, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Patent number: 9821054
    Abstract: A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: November 21, 2017
    Assignee: Turnstone Limited Partnership
    Inventors: Byram Bridle, Brian Lichty, Yonghong Wan, Jean-Simon Diallo, Chantal Lemay, John Bell
  • Patent number: 9802986
    Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: October 31, 2017
    Assignee: INTERNATIONAL AIDS VACCINE INITIATIVE
    Inventors: Christopher L. Parks, Ivo Lorenz, Sanjay K. Phogat, Timothy J. Zamb
  • Patent number: 9790256
    Abstract: Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV18 and/or HPV16.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: October 17, 2017
    Assignee: JANSSEN VACCINES & PREVENTION B.V.
    Inventors: Evelien Margaretha Bunnik, Jerome Hubertina Henricus Victor Custers, Gerrit Christiaan Scheper, Koen Oosterhuis, Taco Gilles Uil, Selina Khan
  • Patent number: 9782473
    Abstract: Disclosed are yeast-based immunotherapeutic compositions, human immunodeficiency virus (HIV) antigens, and fusion proteins for the treatment and/or prevention of HIV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HIV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HIV and/or symptoms thereof.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: October 10, 2017
    Assignee: GLOBEIMMUNE, INC.
    Inventors: Thomas H. King, David Apelian
  • Patent number: 9783788
    Abstract: The present invention relates to the technical field of porcine pseudorabies virus, and more particularly to a porcine pseudorabies virus (PRV)-YF strain, with the preservation No. of CCTCC No. V201502. The present invention also provides an application of the porcine pseudorabies virus (PRV)-YF strain in preparing an inactivated vaccine of the porcine pseudorabies virus, the inactivated vaccine of the porcine pseudorabies virus and a preparation method thereof. It is proved through an immune efficacy evaluating test and a safety test that the inactivated vaccine of the porcine pseudorabies virus has good immune protective efficacy and is safe for weaned piglets, replacement gilts, pregnant sows and the like.
    Type: Grant
    Filed: January 31, 2016
    Date of Patent: October 10, 2017
    Assignees: Zhaoqing Dahuanong Biological Medicine Co., Ltd, South China Agricultural University
    Inventors: Ruiai Chen, Hongliang Huang, Changbao Ren, Xiaoyu Xie, Zheng She, Xuanzi Zhan, Xiaoxiong Deng, Manhua Tang
  • Patent number: 9771413
    Abstract: Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: September 26, 2017
    Assignees: Neurimmune Holding AG, University of Zurich
    Inventors: Jan Grimm, Roland Martin, Benoit Combaluzier, Ivan Jelcic
  • Patent number: 9738691
    Abstract: Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: August 22, 2017
    Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD.
    Inventors: Shaowei Li, Minxi Wei, Xianglin Kong, Yingbin Wang, Jun Zhang, Ningshao Xia
  • Patent number: 9732358
    Abstract: The present invention includes the Paramyxovirus Parainfluenza Virus 5 (PIV5) as an oncolytic agent for treating various cancers, including, but not limited to breast cancer, lung cancer and melanoma. PIV5 oncolytic agents include both wild type PIV5 and various recombinant PIV5 constructs. Recombinant PIV5 constructs may include PIV5 lacking the conserved C-terminus of the V protein (PIV5VAC), PIV5 with mutations in the N-terminus of the V/P protein (PIV5CPI?), and PIV5 expressing MDA-7/IL-24 (rPIV5-MDA7), rPIV5-V/P-CPI?, rPIV5-CPI+, rPIV-Rev, rPIV5-RL, rPIV5-P-S157A, rPIV5-P-S308A, rPIV5-L-A1981D, rPIV5-F-S443P, rPIV5-MDA7, rPIV5ASH-CPI?, or rPIV5ASH-Rev. Also included are methods of making and using such oncolytic agents and compositions including such oncolytic agents.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: August 15, 2017
    Assignee: University of Georgia Research Foundation, Inc.
    Inventor: Biao He
  • Patent number: 9707285
    Abstract: In one aspect, a method of treating cancer in a mammal is provided. The method comprises administering to the mammal an oncolytic vector that expresses a tumor antigen to which the mammal has a pre-existing immunity. In another aspect, a method of boosting immune response in a mammal having a pre-existing immunity to an antigen is provided comprising intravenous administration to the mammal of a B-cell infecting vector that expresses the antigen.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: July 18, 2017
    Assignee: Turnstone Limited Partnership
    Inventors: Brian Lichty, Byram Bridle, Yonghong Wan, Jonathan Bramson
  • Patent number: 9701721
    Abstract: Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV16.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: July 11, 2017
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Evelien Margaretha Bunnik, Jerome Hubertina Henricus Victor Custers, Gerrit Christiaan Scheper, Koen Oosterhuis, Taco Gilles Uil, Selina Khan
  • Patent number: 9700615
    Abstract: The present invention is directed to methods for administering antigenic material to a patient as a vaccine against an infection comprising providing both an antigenic material specific to the desired immunological response desired plus an adjuvant comprised of a peptide of a sequence derived from the sequence of pneumococcal surface adhesin A protein (PsaA). Preferably the peptide comprises a sequences derived from one or more sequences of PsaA that contain the epitope regions or contiguous amino acids of SEQ ID NOs 1 or 2. The invention is also directed to vaccine compositions containing adjuvant of the invention and also adjuvant compositions of the invention.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: July 11, 2017
    Assignee: Serum Institute of India Pvt. Ltd.
    Inventor: Subhash V. Kapre
  • Patent number: 9688727
    Abstract: The present invention provides recombinant adenoviral compositions and methods for their use in treating disorders associated with epithelial tissues.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: June 27, 2017
    Assignee: University of Washington
    Inventors: Andre Lieber, Hongjie Wang
  • Patent number: 9683997
    Abstract: The present invention relates to the development of a monoclonal antibody which has binding activity to many high-risk types of HPV, etc. The present invention also provides a simple and high-throughput method for measuring cross-neutralizing antibody titers, which is used for assay of cross-neutralizing antibody against HPV in serum samples from subjects, etc. The method of the present invention for measuring cross-neutralizing antibody titers comprises the steps of: preparing a monoclonal antibody against a peptide having a specific amino acid sequence common to high-risk types of HPV; and assaying cross-neutralizing antibody using this monoclonal antibody.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: June 20, 2017
    Assignee: Japan Health Sciences Foundation
    Inventors: Seiichiro Mori, Tadahito Kanda
  • Patent number: 9676819
    Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: June 13, 2017
    Assignee: INNAVAC PTY LTD
    Inventors: David Charles Jackson, Amabel Tan, Weiguang Zeng
  • Patent number: 9676828
    Abstract: The present invention relates to rearranged molecules of (a) a specific TT virus sequence and (b) a nucleotide sequence encoding a polypeptide showing homology to mammalian proteins associated with cancer and autoimmune diseases that are capable of replicating autonomously for use in diagnosis, prevention and treatment of diseases like cancer and autoimmunity.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: June 13, 2017
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Ethel-Michele De Villiers, Harald Zur Hausen
  • Patent number: 9657063
    Abstract: A porcine circovirus type-2 (PCV2) immunogenic composition includes an antigenic peptide. The antigenic peptide is a non-arginine-rich peptide of a PCV2 open reading frame 2 (ORF2) and/or a recombinant fusion protein having the non-arginine-rich peptide of the PCV2 ORF2, a PE peptide, and a KDEL signal peptide. The number of arginines of the non-arginine-rich peptide of the PCV2 ORF2 is not greater than half of the number of arginines of the arginine-rich domain of the N terminal of the PCV2 ORF2.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: May 23, 2017
    Assignee: SBC VIRBAC LIMITED
    Inventors: Tsun-Yung Kuo, Hsu-Chung Gabriel Chen, Shu-Hsiang Yang, Yu-San Chen
  • Patent number: 9657088
    Abstract: The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: May 23, 2017
    Assignee: Heidelberg ImmunoTherapeutics GmbH
    Inventors: Michael Roggendorf, Anna-Maria Eis-Hübinger, Jürgen Krauss, Karl Eduard Schneweis, Michaela Arndt, Adalbert Krawczyk, Evelyn Exner, Martin P. Däumer